August 9, 2022

Biden’s Back-to-Back COVID Diagnoses Challenge Administration’s Narrative on His Health: Report

“Instead of the narrative of beating the virus… the president’s rebound case reinforces the uncomfortable reality that the pandemic refuses to go away, ” reports New York Times.

The chief executive tested positive for COVID-19 a second time on Sunday, just days after their announcement Wednesday that he had been given the all-clear following final week’s diagnosis.

PresidentJoe Biden’s COVID rebound case, while gentle, will undermine the White House’s narrative on his health insurance and “ complicate his hard work to turn his illness right into a positive story, ” The brand new York Times believes.

In its story to the president’s re-diagnosis, the generous newspaper  pointed out   that the 79-year-old leader, whom detractors have been attacking mercilessly over possible signs of dementia and a series of slips, falls, and flubs, has demonstrated eagerness to display his actual physical prowess, “ especially when he forecasts plans to run for the second term in 2024. ”

Biden, the NYT recalled, showed himself working at the Whitened House throughout his very first quarantine after testing optimistic on July 21, and then sought to present Wednesday’s COVID all-clear as a “ triumphal return to work in person. ”

“ Instead of the narrative of beating the virus, however , the president’s rebound case reinforces the unpleasant reality that the pandemic will not go away. Although the death cost has fallen dramatically, Covid-19 remains a fact of life for Americans, some of whom have been infected multiple times, ” the paper noted.

It added which the re-diagnosis would push back the particular president’s plans to travel the nation to push his plan and campaign in support of Democratic allies, who face the walloping at the upcoming November midterm elections, according to recent  polling .

The NYT furthermore questioned what impact Biden’s re-diagnosis might have on Pfizer – the pharma huge and  advertising revenue moneybag   that manufactures Paxlovid – the particular oral drug taken by Biden after his first COVID-19 diagnosis which has come under growing scrutiny for alleged “ rebound” cases.

“ Paxlovid rebound has become a source of debate within the scientific community and among Covid patients, ” the newspaper carefully explained, acknowledging and that the real number of rebound cases is “ most likely significantly higher” than the lower single digits referred to by Pfizer in its studies.

“ Either way, experts stressed that Paxlovid has been notably successful in avoiding more severe Covid-19 illnesses plus hospitalizations, ” the papers stressed, referencing the widely used talking point in ALL OF US media referring to both COVID treatments and vaccines. Formerly, when studies revealed the FDA-approved Pfizer, Moderna, plus Johnson & Johnson jabs were subject to a “ breakthrough infection” rate of  25 percent or more , particularly against Omicron versions, the pharmaceutical companies, federal government, and media shifted the particular goal posts, pointing instead to their “ protection towards severe illness, hospitalization and death. ”

In a video address following his re-diagnosis Saturday, Chief executive Biden, who had been double-vaxxed and double-boosted before getting COVID the first time,   emphasized   that he had been “ feeling fine, ” that “ everything great, ” and that he would end up being “ working from home for the following couple days” with Commander, his German Shepherd.


Bizzaro Biden Emerges Juiced To The Gills

Leave a Reply

Your email address will not be published. Required fields are marked *